Adolescent Idiopathic ScoliosisKIDSNCT06042699
Kids With Iron Deficiency and Scoliosis
A study testing Oral ferrous sulfate in people with Adolescent Idiopathic Scoliosis and Neuromuscular Scoliosis, run by Columbia University at 1 site in United States.
Trial summary
This study is a randomized controlled trial of preoperative oral iron supplementation, to identify whether iron deficiency is a modifiable risk factor for adverse surgical outcomes such as red blood cell transfusion and diminished postoperative cognitive and physical capacity in adolescents undergoing scoliosis… Read more about this study
- Who is it for?
- Ages 10 to 26 yearsHealthy volunteers can take part
- Conditions the study is for
- Adolescent Idiopathic Scoliosis, Neuromuscular Scoliosis, Perioperative/Postoperative Complications
- What is being tested?
- Oral ferrous sulfate
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 275 participants
- Where
- 1 siteUnited States
- Study dates
- 11 Jan 2024to 1 Feb 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 26 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- 10-26 years old;
- diagnosis of scoliosis or kyphosis;
- self-reported ability to swallow a tablet;
- spinal fusion procedure planned approximately 6 to 24 weeks from an orthopedic surgical clinic visit at which patient agrees to phlebotomy for screening blood work;
- serum ferritin less than or equal to 25 µg/L.
Who cannot join
- taking or planning to take iron-containing supplement on patient's own volition, and not willing to stop for duration of study;
- taking or planning to take iron-containing supplement as prescribed or recommended under the care of a physician;
- Hg <10mg/dL if post-menarchal, Hg < 11 if premenarchal or male
- C-reactive protein > 10 mg/L
- receiving nutritional support by report in the medical chart;
- self-reported history of hypersensitivity reaction to iron-containing supplements;
Show all 12Show fewer
- self-reported history of or suspected non-iron deficient hematologic disorder;
- self-reported history of iron overloaded state such as hereditary hemochromatosis or hemosiderosis;
- objection to receiving red blood cell transfusions;
- current pregnancy (by self-report);
- prisoners;
- patient or parent decides against study participation.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Columbia University Medical Center
New York, New York, 10032
Lisa Eisler, MD, ldl2113@cumc.columbia.edu
Lisa Eisler, MD
About this study
Official title: Kids With Iron Deficiency and Scoliosis (KIDS) Study
This study is a randomized controlled trial of preoperative oral iron supplementation, to identify whether iron deficiency is a modifiable risk factor for adverse surgical outcomes such as red blood cell transfusion and diminished postoperative cognitive and physical capacity in adolescents undergoing scoliosis surgery.
Research Question(s)/Hypothesis(es):
Read more
Primary
- Iron supplementation will reduce the incidence of perioperative RBC transfusion in iron deficient scoliosis patients undergoing spinal fusion.
Secondary
- Iron supplementation will reduce postoperative neurocognitive functional declines in iron deficient scoliosis patients undergoing spinal fusion.
- Iron supplementation will improve patient-reported physical functioning in iron deficient scoliosis patients undergoing spinal fusion.
Read the detailed description
Adolescents undergoing spinal fusion surgery for scoliosis are poised to benefit from preoperative iron supplementation. Spinal fusion carries a risk of large surgical blood losses and perioperative red blood cell transfusion, which are associated with adverse outcomes in this population. These patients are mostly adolescent females, a group more susceptible to iron deficiency and resulting anemia at baseline due to iron losses with menses, and who suffer an additional insult to iron stores during surgery. Nevertheless, iron status is not routinely monitored in this setting and there is no standard of care for preoperative iron supplementation. Iron is a nutritionally essential trace element important not only for red blood cell production, but also for muscle function and neurotransmitter synthesis and signaling. Therefore, the treatment of preoperative iron deficiency is an important target for optimizing hemoglobin prior to surgery, reducing transfusion rates and associated complications such as alloimmunization, and improving patient outcomes. On its own and as the primary cause of anemia, iron deficiency was identified by the investigator's team as the only risk factor for transfusion which is modifiable preoperatively.
In addition, iron supplementation is shown to alleviate impairments of physical and cognitive capacity associated with even mild forms of iron deficiency in adolescent females. A pilot study conducted at the investigator's institution identified iron deficiency in 36% of scoliosis patients prior to surgery, with preoperative iron status highly correlated with iron status during surgical recovery. Consequently, the investigator plans to examine iron deficiency as a modifiable risk factor for transfusion and impaired postoperative cognitive and physical capacity in this vulnerable population. Previous trials of brief iron interventions in high-risk adult surgical patients, mostly with unknown iron status, do not inform the care of iron deficient adolescents and were not designed to address postoperative functional outcomes. This study will therefore perform a single-center randomized controlled trial in which adolescents with scoliosis will be screened for iron deficiency (n = ~275), and iron-deficient adolescents with scoliosis (n = ~90) will be randomized to a preoperative regimen of daily oral iron or placebo, to test the hypotheses that preoperative iron supplementation 1) reduces the rate of red blood cell transfusion, 2) improves postoperative neurocognition compared to a preoperative baseline, and 3) improves patient-reported physical functioning during recovery. Results will ultimately improve outcomes in this vulnerable pediatric population and provide evidence for patient blood management approaches to reduce transfusions amid recent severe blood shortages.
- Conditions
- Adolescent Idiopathic Scoliosis, Neuromuscular Scoliosis, Perioperative/Postoperative Complications, Iron Deficiencies, Anemia, Spinal Fusion
- Being tested
- Oral ferrous sulfate, Oral placebo tablet
- Medical subject headings
- Postoperative Complications, Iron Deficiencies, Anemia, Postoperative Cognitive Complications
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Oral ferrous sulfateDietary supplement
Oral ferrous sulfate 325mg is used as a dietary supplement providing 65mg elemental iron.
Oral placebo tabletDietary supplement
Oral placebo tablet provided as placebo comparator.
| Study group | Role | What they receive |
|---|---|---|
| Oral ferrous sulfate | Experimental | Participants will receive oral ferrous sulfate tablets, 325mg (65mg elemental iron). Tablets are to be taken once daily for 3-6 months prior to surgery as time allows. Receives: Dietary Supplement: Oral ferrous sulfate |
| Oral placebo tablets | Placebo comparator | Participants will receive placebo tablets. Tablets are to be taken once daily for 3-6 months prior to surgery as time allows. Receives: Dietary Supplement: Oral placebo tablet |
| Observational follow-up | No intervention | Participants who do not qualify for randomization may be invited to complete study measures through postoperative follow-up as part of an observational study. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of perioperative RBC transfusion in iron deficient scoliosis patients undergoing spinal fusion
The patients that received a red blood cell transfusion either during procedure or postoperatively during t surgical hospitalization will be tallied.
Measured: 4 to 30 days
Secondary outcomes (3)
Percentage of Patients that experienced postoperative decline in neurocognitive function
The Cognitive Battery of the NIH Toolbox is a brief, valid, and reliable instrument designed to provide outcome measures in epidemiologic and longitudinal research that can be used for comparisons across a wide range of studies and populations. Individual measure scores in the battery reflect Executive Function, Attention, Verbal and Nonverbal Memory, Language, Processing Speed, and Working Memory, yielding composite score. A decline of function is measured by comparing the mean change from baseline in the Cognitive Function Composite Scores in the study groups. Higher raw scores reflect higher function in the tested domains, and age-adjustment is then performed such that Age-Corrected Standard scores compare the score of the test-taker to those in the NIH Toolbox nationally representative normative sample at the same age, where a score of 100 indicates performance that was at the national average for the test-taking participant's age.
Measured: 3-6 months
Percentage of patients that experienced postoperative decline in self-reported physical capacity
The PROMIS pediatric measures are a NIH Roadmap initiative to provide access to valid and reliable self-reported measures of health-related quality of life in children and adolescents. The PROMIS measures are scored on a T-score metric with a mean of 50 and SD of 10 in the general population in the United States. Higher PROMIS symptom scores indicate increased symptom burden, and higher PROMIS function scores indicate increased functioning. Decline would be identified through a mean change (decrease) from baseline in the Physical Functioning - Mobility scores; with secondary hypotheses for Physical Functioning - Upper Extremity, Physical Activity, and Fatigue.
Measured: 3-6 months
Volume of perioperative RBC transfusion
The volume that each patient receives either during procedure or postoperatively during surgical hospitalization will be summed and average calculated.
Measured: 4 to 30 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2023
- Study start11 Jan 2024
- Primary completion15 Dec 2027 (estimated)
- Study completion1 Feb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Adolescent Idiopathic ScoliosisStudies of the same condition, open and under way.
- More trials run by Columbia UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double blind placebo-controlled randomized controlled trial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 275 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Columbia University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of General Medical Sciences (NIGMS)
- Responsible party
- Principal investigator, Lisa Eisler, Columbia University
- Investigators
- Lisa D Eisler, MD, Principal investigator, Columbia University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06042699
- Sponsor's protocol ID
- AAAU2577
- Other IDs
- K23GM152933-01
- Acronym
- KIDS
- Status last verified
- Jun 2026
- First submitted
- 12 Sep 2023
- Last updated
- 26 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: IPD will not be shared.